Overview

Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

Status:
Not yet recruiting

Trial end date:
2025-03-20

Target enrollment:

Participant gender:

Summary

Major depressive disorder (MDD) is a significant cause of disability that affects approximately 16% of the world's population and is associated with chronic inflammation. Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a procaspase-1 precursor. It is well known that a variety of danger signals, such as pathogen-associated molecular patterns and danger-associated molecular patterns can activate NLRP3 inflammasome

Phase:

Phase 2

Details

Lead Sponsor:

Tanta University

Collaborators:

Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University
Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University
Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University

Treatments:

Atorvastatin
Dapagliflozin
Fluoxetine